second we have another one, i call it a nasdaqy name, regeneron.tremendous growth biotech company, trades at 17 times earnings you notice a fantastic macular degeneration franchise, a growing cancer franchise, and amazingly strong anti-inflammatory business this is one of the first stocks i recommended on "mad money" when it was around 5 now it's at 723 and change i wish they'd split the stock, though, make it so you'd be more likely to buy it there are plenty of high-quality ones, especially going into a slowdown i like -- i know amgen's always doing something good i'm not as big a fan of biogen here i like their alzheimer's drug but i don't think it will be successful as lily's which i prefer and which is one of the reasons i own it for the charitable trust and spent so much time analyzing for the investing club i honestly could have populated the whole segment with nasdaq drug names i even have some good things to say about astrazeneca, and if you put a gun to my head and i say -- i bet you gilead has something positive although i haven't seen i

>> you know, on regeneron i like the stock. it and i kind of feel the way jenny does, i think it's probably a bit late when the stock starts moving like this but in terms of this sector i think you've got to own it for -- frank, i really want to disclaim here. worries the hell out of me when i start agreeing with weiss. i want to say it to get out there. okay, look, whether it's a pharmaceutical it's health care core, these are recession defensive stocks we know the area and how the demographic in this country is music. we know the prices have been rising i think in terms of balance sheets they're fabulous, diversified. this is a place to hide and i think also benefit as stock prices recover i'm very happy i've got this core in my portfolio >> we are watching health care opportunity xlb fractionally down today up next our turn of the day. this sector headed for its worst week in just about five months the committee debates what that cod snangulbeigli and how they're playing the space. much more coming up in half time stay with

>>> and we're live from jpmorgan health care, a conversation with the chooef of regeneron is coming upat and more after the eak. i screwed up. mhm. i got us t-mobile home internet. now cell phone users have priority over us. and your marriage survived that? you can almost feel the drag when people walk by with their phones. oh i can't hear you... you're froze-- ladies, please! you put it on airplane mode when you pass our house. i was trying to work. we're workin' it too. yeah! work it girl! woo! i want to hear you say it out loud. well, i could switch us to xfinity. those smiles. that's why i do what i do. that and the paycheck. health care conference in san francisco. that's where we find meg alongside another special guest. >> dr. len schleifer joining us. good to see you. >> good to see you. >> it seemed to be over the miss with your big eye drug what were the dynamics there some folks said you said it was temporary but they said maybe increasing competition >> have in mind that sometimes the situation like this where warren buffett would say, occasionally they would put a company

i like regeneron there are more important things than earnings on friday. we had the labor department's non-pharm payroll report and the presumption is the fed has an idea about the numbers before the wednesday meeting. who knows. if wage inflation is strong, the quarter point move will be criticized if it's weaker, we'll hear about the hard landing again but if they sneak in a 50-basis point hike, it will be totally unexpected and could repeal the rally even if they try to telegraph it ahead of time bottom line, after the tsunami of earnings and wednesday fed meeting, this coming hell week will be over wish me luck because i need it let's go to george in pennsylvania, george >> caller: how are you doing, jim? it's been two years since the meme stock mania kicked off. can i have your blessing on a small speculative position on amc? >> amc, you're absolutely right. it's been two years. i'll bless a small speculative position i only do it for one reason. because you called it speculative. the movie theater business is not doing well michael in south carolina,

stuart: regeneron, they are sharply lower. down 8%. what is their problem?ren: they expect sales for one of their blockbusters eye drugs $6 billion in change. analysts are expecting 3 billion-dollars more. they say much lower than you expect. they're getting a discount as a result. stuart: amazon up nicely. that is the nice gain. 3%. the story? lauren: jeffries says cost pressures will ease backs half, second half of the year for amazon. stuart: 3% gain knotted bad for amazon. last one, elon musk is asking a judge to move his shareholder trial out of california. where does he wants to move it to? lauren: austin, texas. that is where his other headquarters. a san francisco jury will be very biased against me, what is going on at twitter, all the job cuts. stuart: that is a good point. lauren: but this is an old lawsuit. the shareholder lawsuit back in 2018, when the take private one, shareholders accused him of manipulating tesla stock price when he said funding was secured. now there is finally a hearing on this, the relocation hearing is january 13th on fri

but if you get a stock like regeneron, which is doing everything right and won't be affected by a slowdown, don't be -- don't mind that it was in the top part of the -- of the nasdaq 100 don't be put off by winners. >> what do you got tonight on the show >> well, i like to go over the beginning of the year the best investments for the dow. i'm going to go through s&p and nasdaq i pick the bottom and then the top and try to find out the best and for the club, david, at 2:00 today, i'm starting the home stretch with jeff marks, a podcast. you remember the club? it will be around 2:00ish. i missed you and i'm glad to see you. >> good to be back again. >> it is good to be back. >> soon enough we'll have our other partner as well. >>> we have a lot more ahead this morning when we come back, we'll have a lot more on tesla stock. take a look, down another 8.7% after those delivery and production numbers did not come in where analysts expected keep it here >>> good tuesday morning, everybody. welcome to another hour of "squawk on the street. i'm david faber with sara eisen and mike santoli carl an

bell the health care theme given jpmorgan >> want to put out the kinds of what happens out there, regeneronalks about how sales may not be as drug on their eye drug and monoclonal antibodies, all known variants of covid-19 when you're out there you got to take the good with the bad may have something new but may have something that's lacking of their old. it's a hard conference i've covered for a number of years and got to be very, very cognizant of what wall street is looking for and what the company says about the future because they're often very different, so i just -- i bring it up as something that tells you don't jump when you hear something new is something old may be faltering. >> a bunch of smaller health care deals coming out of that conference too, carl we'll get to that when we watch them trade this morning. >> yeah, news on moderna on this paxlovid china thing got a little bit of the needle moving some of those talks are broken down regarding insurance we talked about it friday. here's the opening bell and the cnbc realtime exchange at the big board celebrating 20 years educat

. >> while we're at it, regeneron gets an upgrade at jpmorgan and dupixent. >> yeah, they're in a quandary. the stock got completely hammered and len, the ceo, reminded me, look, you're missing the whole point. people are missing that it's not ilea anymore, it's pixent. it's a wonder drug a lot of people take it if humira doesn't work. it's a wonder drug it's got something very real people who sold the stock made a mistake. i think the stock's very good. very good. >> bunch of consumer finance names today, jim aly i think is up double digits this morning on a beat revenue ahead. looking at assuming used vehicle prices fall another 13% this year. >> shorted name. people felt they would be able to discover and cap one. cap one didn't come back the ones that everyone are really worried about, buy now, pay later. more familiar with the concept of buying something than paying for it. >> maybe they were familiar with that concept and they thought this would let them avoid that yeah >> and the companies themselves, nobody thought -- who would have dreamed that jay powell, i hope he's feeling bett

. >> you can't just say we'll take that money, we're going to buy regeneron and we're going to combineand that's our game plan. you can't do that. w will you give the guy like five minutes. give dr. bourla five minutes he bought the migraine drug. i think it will be one of the biggest -- >> how about mcdonald's? >> spotify is up almost 10%, 9.5% the company did have monthly average user growth, 33 million net additions, 20% above last year $4 489 million. ten million above guidance total revenue up 18% year over year still losing presentity of money. >> the cash flow was bad. >> cash flow was negative. >> that's called bad >> part of the plan -- i understand it's part of the plan to spend a lot of money and gain as much share as they possibly can. you know the strategy. >> we don't like that typically. >> at least they gain more users than people part. >> they see q1 as the low point for margins, 5 million podcasts, not going to revamp the podcast business. >> i'm playing devil's advocate to your incredibly rosey analysis >> compared to some companies losing money. >> by the way, take

up, jim cramer first take on the trading day and then at 10:00 don't miss a first interview with regeneron at a vrbo the host doesn't stay with you. because without privacy in your vacation home, it isn't really a vacation... ...is it? [birds chirping] dad, we got this. we got this. we got this. we got this. we got this. yay! we got this. we got this! life is for living. we got this! let's partner for all of it. edward jones >>> let's get town down to the new york stock exchange. jim cramer joins us now. a whole bunch of things we could talk about this morning. i was curious about what you thought of -- we had the ceo of t-mobile and we were talking about the capital 100 list and we talked about what is happening with inflation and with the customer. and then we got into the apple of it all. where are you on apple right now? he said that inventories are back and i don't know what you think that means about catch up in the last quarter versus this quarter at this point. >> well, i think that, look, mike siefert is unbelievable and he is the guy with a better touch on apple that an all of th